MetPath Review Center

Enriching the minds of laboratory scientists worldwide

MetPath's Team

MetPath's team of lecturers is dedicated, not just refresh, but to re-educate all medical technology graduates in preparation for any licensure exams in medical laboratory science.

The team is headed by Howard Denila and his partners who are medtech board top-notcher, sumacumlaude, masters and doctorate degree holder, and are registered medical technologists in the Philippines and in the US (AMT and ASCP-BOR).

We ensure quality review programs by providing all the necessary review books and materials, extending the time of discussions for each subjects, while making sure that each students will acquire all the knowledge and information they need before taking their respective exam.

Congratulations! (AUG - SEP 2017)

Myra Leona Lopez, MLS(ASCP)
Mikel Rovic Luza, MLS(ASCP)
Merry Antonette Callanta, MLS(ASCP)
Khristian Misola, MLS(ASCP)
Maritess Tuyco, MLS(ASCP)
Vera Grace Culango, MLS(ASCP)
Janeen Campana, MLS(ASCP)
Nikka Franco, MLS(ASCP)
Oryl Ann Arnoco, MLS(ASCP)


Main Center

104 Jaltan Bldg.
CM Recto cor Bonifacio Street,
Davao City 8000, PHL         

DTI Cert. No. 00147471

Share MetPath to a friend

Recent Diagnostic Posts

Safety Tests Of Ebola Vaccines To Start This Fall.

 

The AP (8/15, Perrone, Neergaard) reports that safety trials are to begin for two experimental Ebola vaccines. Safety tests “typically are performed on a few dozen to 100 people.” The first, “developed by researchers at the National Institutes of Health” and GlaxoSmithKline should be tested in the next few months and is “based on a chimpanzee adenovirus.” Dr. Anthony Fauci has explained that it is “purely preventive, more aimed at giving it to the health care workers who put themselves at considerable danger.” The second, developed by researchers at the Canadian national laboratory and NewLink Genetics of Ames, Iowa, is expected to be tested “in up to 100 health volunteers with the FDA” though the timetable has not been set. The NIH is also supporting development of “at least two other candidate Ebola vaccines,” the first from Crucell, which “could begin human testing by late 2015,” and the second from Profectus Biosciences.